在第一阶段研究中,CureVac的质母细胞瘤疫苗显示出有前途的安全性和有效性,为第二阶段铺平了道路. CureVac's glioblastoma vaccine in Phase 1 study shows promising safety and efficacy, paving the way for Phase 2.

CureVac公司的CVGBM癌症疫苗在ESMO 2024年大会上报告的对血浆瘤的第一阶段研究中取得了令人乐观的成果。 CureVac's CVGBM cancer vaccine has shown promising results in a Phase 1 study for glioblastoma, reported at the ESMO 2024 Congress. 77%的病人接受了疫苗诱发的针对特定癌症的T细胞反应,其中84%是新生成的。 The vaccine induced cancer-specific T-cell responses in 77% of patients, with 84% of these responses newly generated. 它展示了一种有利的安全特征,没有明显的毒性。 It demonstrated a favorable safety profile, with no significant toxicities. 为下一阶段选择了100微克的剂量,该阶段已开始让病人入院,这标志着癌症免疫疗法的进展。 A 100 µg dose has been chosen for the next phase, which has started enrolling patients, marking progress in cancer immunotherapy.